Vivus Inc (NASDAQ:VVUS) Short Interest Decreased By 6.42%

June 14, 2018 - By Christine McCrea

Investors sentiment increased to 1 in Q1 2018. Its up 0.43, from 0.57 in 2017Q4. It improved, as 7 investors sold VIVUS, Inc. shares while 12 reduced holdings. 8 funds opened positions while 11 raised stakes. 22.03 million shares or 14.97% less from 25.91 million shares in 2017Q4 were reported.
State Street Corporation owns 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 103,137 shares. Virtu Financial Llc holds 0% or 126,673 shares. Northern Tru has invested 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Blackrock stated it has 0% in VIVUS, Inc. (NASDAQ:VVUS). Hanson Mcclain, a California-based fund reported 250 shares. 32,226 are owned by Goldman Sachs Gru. First Manhattan Com has 56,800 shares for 0% of their portfolio. Whittier Communications invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Jpmorgan Chase accumulated 2,500 shares or 0% of the stock. Moreover, Stratos Wealth Ptnrs Ltd has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 300 shares. First Trust Advsr Limited Partnership stated it has 95,665 shares. Plante Moran Finance Advsrs Lc holds 0% or 190 shares in its portfolio. Next Fincl Incorporated reported 33,057 shares. D E Shaw And has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Grp Inc One Trading L P stated it has 34,368 shares or 0% of all its holdings.

The stock of Vivus Inc (NASDAQ:VVUS) registered a decrease of 6.42% in short interest. VVUS’s total short interest was 4.90 million shares in June as published by FINRA. Its down 6.42% from 5.24 million shares, reported previously. With 251,800 shares average volume, it will take short sellers 20 days to cover their VVUS’s short positions. The short interest to Vivus Inc’s float is 5.39%.

The stock decreased 0.56% or $0.0046 during the last trading session, reaching $0.8225. About 603,111 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 18.39% since June 14, 2017 and is downtrending. It has underperformed by 30.96% the S&P500.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $87.23 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

More news for VIVUS, Inc. (NASDAQ:VVUS) were recently published by: Streetinsider.com, which released: “VIVUS (VVUS) Closes Acquisition of PANCREAZE and Previously Announced Financing Transaction” on June 11, 2018. Benzinga.com‘s article titled: “Benzinga Pro’s 5 Stocks To Watch Today” and published on June 11, 2018 is yet another important article.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.